Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) EPS (Basic): 2017-2025

Historic EPS (Basic) for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to -$0.12.

  • Aclaris Therapeutics' EPS (Basic) fell 9.09% to -$0.12 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.58, marking a year-over-year decrease of 203.85%. This contributed to the annual value of -$1.71 for FY2024, which is 34.65% down from last year.
  • Aclaris Therapeutics' EPS (Basic) amounted to -$0.12 in Q3 2025, which was up 7.69% from -$0.13 recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year EPS (Basic) high stood at -$0.02 for Q4 2023, and its period low was -$1.21 during Q4 2024.
  • Moreover, its 3-year median value for EPS (Basic) was -$0.15 (2024), whereas its average is -$0.30.
  • In the last 5 years, Aclaris Therapeutics' EPS (Basic) skyrocketed by 95.12% in 2023 and then crashed by 5,950.00% in 2024.
  • Over the past 5 years, Aclaris Therapeutics' EPS (Basic) (Quarterly) stood at -$0.37 in 2021, then dropped by 10.81% to -$0.41 in 2022, then spiked by 95.12% to -$0.02 in 2023, then slumped by 5,950.00% to -$1.21 in 2024, then fell by 9.09% to -$0.12 in 2025.
  • Its EPS (Basic) stands at -$0.12 for Q3 2025, versus -$0.13 for Q2 2025 and -$0.12 for Q1 2025.